A study analyzing 92,000 people found semaglutides, found in GLP-1 drugs such as Ozempic, were linked to a 33% lower risk of ...

Medicare Part D spent a total of $4.6 billion on Ozempic in 2022, based on the most recent data we have from the Centers for Medicare & Medicaid Services. This spending covered 780,253 ...

Medicare shelled out $5.7 billion on Ozempic and other similar diabetes drugs in 2022, up from $57 million in 2018, according to a new KFF analysis.

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.